Course and complications of influenza A in seniors over 65 years of age

Cent Eur J Public Health. 2024 Sep;32(3):155-159. doi: 10.21101/cejph.a7877.

Abstract

Objectives: Influenza A and B viruses cause epidemics every year, with approximately 3-5 million serious cases and about 290,000 to 650,000 deaths worldwide. Most patients die from bacterial complications of influenza. The aim of our study was to describe the clinical pictures of influenza and the development of the complications in seniors over 65 years of age, who were treated in University Hospital Pilsen. The course of the disease and changes in laboratory parameters were evaluated with regard to the method of treatment performed.

Methods: A descriptive retrospective study was performed. Clinical and laboratory data of seniors with the diagnosis of influenza were extracted from electronic medical records and later analysed. The data were processed with Excel 2016 and Statistica.

Results: A collection of 261 seniors, of whom 218 were hospitalized and 43 treated in an outpatient setting, has been studied. Patients who later developed complications had elevated values of CRP, procalcitonin, urea, and creatinine. The antiviral drug oseltamivir was administered to 226 of 261 seniors. Forty-seven seniors (18.0%) died from influenza and its complications (severe pneumonia with acute respiratory insufficiency or heart failure).

Conclusions: The course of influenza in seniors was usually more severe and required hospitalization along with antiviral treatment. The mortality rate in the monitored group exceeded 18%. Annual timely vaccination, but also other preventive measures, and maybe considering other risk groups are methods to prevent severe or even fatal cases of influenza.

Keywords: complications; influenza; respiratory infections; seniors; vaccination.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antiviral Agents* / therapeutic use
  • Female
  • Hospitalization / statistics & numerical data
  • Humans
  • Influenza A virus / isolation & purification
  • Influenza, Human* / complications
  • Influenza, Human* / epidemiology
  • Male
  • Oseltamivir / therapeutic use
  • Retrospective Studies

Substances

  • Antiviral Agents
  • Oseltamivir